Gilead will present an update from its HIV cure research program, exploring the immunogenicity and associated safety of amtabafusp alfa (GS-8588), a bispecific T-cell engager, in a Phase 1b study in ...
You receive an order, open the supplier's page, and find it's already sold out. If you have been selling on BUYMA for a while ...
Gilat Satellite Networks is rated buy with a 12-month price target of $9.75, offering 31% upside from current levels. Read ...
Rezdiffra® (resmetirom) to be featured in more abstracts than any other approved or investigational MASH therapyReal-world evidence abstracts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results